Table 4.

Hazard ratios and 95% confidence intervals for plasma tertile, genotype and prostate cancer progression^*

		IL-6 Tertile (Range, pg/mL)			P-value†
	1	2	3	4
	0.13–0.94	0.95–1.38	1.39–2.13	2.14–21.0
All cases, N	151	150	151	150
HR (95% CI)	1.00 (Ref)	0.68 (0.37, 1.22)	0.80 (0.45, 1.42)	1.22 (0.71, 2.10)	0.18
BMI<25, N	102	85	87	78
HR (95% CI)	1.00 (Ref)	0.47 (0.19, 1.17)	0.75 (0.35, 1.60)	1.73 (0.86, 3.51)	0.02
BMI≥25, N	48	65	64	72
HR (95% CI)	1.00 (Ref)	0.86 (0.38, 1.96)	1.10 (0.44, 2.75)	0.82 (0.36, 1.88)	0.65
		CRP Tertile (Range, mg/L)
	1	2	3	4
	0.02–0.41	0.42–0.83	0.84–1.68	1.70–29.95	P-value†
All cases, N	150	151	150	150
HR (95% CI)	1.00 (Ref)	0.79 (0.41, 1.52)	1.68 (0.94, 3.03)	1.48 (0.83, 2.66)	0.08
BMI<25, N	103	93	78	78
HR (95% CI)	1.00 (Ref)	0.69 (0.29, 1.69)	1.69 (0.77, 3.70)	1.64 (0.76, 3.51)	0.21
BMI≥25, N	47	58	72	72
HR (95% CI)	1.00 (Ref)	0.84 (0.31, 2.28)	1.58 (0.65, 3.86)	1.31 (0.53, 3.28)	0.19

^*Adjusted for age at diagnosis, tumor stage, grade and BMI (continuous)

^†P-value from score test using a 4-level ordinal variable based on the median within each tertile of plasma levels